Curaleaf Stock Tumbles Amid Uncertainty Over U.S. Cannabis Policy

Curaleaf shares dropped sharply Tuesday as investors reacted to potential setbacks in federal cannabis legalization efforts. The stock fell over 3% following reports that a TRUMP administration health initiative may emphasize risks of THC consumption, contradicting momentum toward nationwide decriminalization.

Market sentiment soured after leaked documents revealed proposed Surgeon General warnings about psychoactive substances. This development casts doubt on the administration's willingness to reschedule marijuana, despite growing bipartisan support for reform. The S&P 500's modest 0.7% decline paled in comparison to Curaleaf's steeper drop.

President Trump's silence on the draft recommendations leaves the industry in limbo. While he previously endorsed state-level cannabis rights, federal policy now appears to be drifting toward caution rather than liberation. The tension between public health concerns and economic opportunity continues to cloud the sector's outlook.